About 30 results found for searched term "CR8" (0.069 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1813 | PCI-24781 | HDAC |
| Abexinostat; CRA-024781 | ||
| PCI-24781 is a novel and potent histone deacetylase (HDAC) inhibitor with IC50 value of 0.43 to 2.7 μM. *The compound is unstable in solutions, freshly prepared is recommended | ||
| M2057 | Dexrazoxane hydrochloride | Topoisomerase |
| Cardioxane, ICRF-187, NSC169780, Zinecard，DXZ | ||
| Dexrazoxane HCl (ICRF-187, ADR-529, DXZ) is an iron chelator that can be used to prevent DOX-induced cardiotoxicity. | ||
| M2129 | Temozolomide | DNA/RNA Synthesis |
| NSC362856; CCRG81045; TMZ | ||
| Temozolomide (TMZ) is an oral DNA methylating, chemotherapeutic agent. | ||
| M2541 | CRT0044876 | DNA/RNA Synthesis |
| NSC 69877 | ||
| CRT0044876 is a potent and selective APE1 inhibitor with IC50 of ~3 μM. | ||
| M3046 | Tacrine hydrochloride | AChR/AChE |
| Hydroaminacrine; NSC72108 HCl | ||
| Tacrine is a centrally acting anticholinesterase and indirect cholinergic agonist. | ||
| M3901 | Combretastatin A4 | Microtubule |
| CRC 87-09, NSC 817373, CA-4 | ||
| Combretastatin A4 (CA-4), which is a natural stilbene isolated from Combretum caffrum, is a microtubule-destabilizing agent that binds to the colchicine domain on β-tubulin and exhibits a lower toxicity profile than paclitaxel or the Vinca alkaloids. | ||
| M4138 | Deucravacitinib (BMS-986165) | JAK |
| BMS986165 | ||
| Deucravacitinib (BMS-986165) is a first-in-class, selective, orally bioavailable inhibitor of TYK2 transitions.Deucravacitinib selectively binds the TYK2 pseudokinase (JH2) structural domain with an IC50 of 1.0 nM and a Ki value of 0.02 nM. Deucravacitinib (BMS-986165) blocks receptor-mediated Tyk2 activation by stably regulating the JH2 structural domain. deucravacitinib also inhibits the IL-12/23 and type I IFN pathways. deucravacitinib may be used in psoriasis research. | ||
| M5609 | Elacridar (GF120918) | P-glycoprotein |
| GW120918 | ||
| Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor. | ||
| M6906 | Levcromakalim | Potassium Channel |
| (-)-Cromakalim; BRL 38227 | ||
| Levcromakalim is a k ir6 (K ATP) channel opener; active enantiomer of cromakalim. | ||
| M7709 | CR8 | PROTAC |
| CR8 is a potent and selective inhibitor of cyclin dependent kinase (CDK1, 2, 5, 7, and 9). | ||
| M7746 | Dexrazoxane | Others |
| ICRF187; NSC169780；DXZ | ||
| Dexrazoxane (ICRF-187, ADR-529, DXZ) is an iron chelator that can be used to prevent DOX-induced cardiotoxicity. | ||
| M10432 | Difelikefalin (CR-845; FE-202845) TFA | Opioid Receptor |
| Disomotide; KORSUVA; MR13A9 TFA | ||
| Difelikefalin (CR-845; FE-202845) TFA is a synthetic peptide and the first-in-class, peripherally-restricted, selective agonist of the κ-opioid receptor (KOR) for studies related to pruritus. | ||
| M15025 | Recombinant Mouse MIP-1α/CCL3 (HEK 293) | Recombinant Proteins |
| Macrophage Inflammatory Protein-1α; CCL-3; LD78α; LD78 alpha | ||
| MIP-1 Alpha, also known as CCL3, G0S19-1 and SCYA3, LD78 Alpha, is an inflammatory chemokine. Mip-1 α belongs to the CCL chemokine family and has 68% homology with MIP-1β. The mature form of MIP-1α contains 69 amino acids, which are present in solution as dimers and tend to accumulate reversibly. Protein structure: MIP-1α (ALA24-ALA92), Accession # : Q5QNW0. | ||
| M15042 | Recombinant Human Adiponectin (CHO) | Recombinant Proteins |
| Acrp-30; GBP-28; Apm-1 | ||
| Adiponectin is an important adipocytokine involved in the control of fat metabolism and insulin sensitivity. It is made only by fat cells and secreted into plasma. Protein structure: Acrp30 (GLU19-ASN244), Accession # : Q15848. | ||
| M15043 | Recombinant Human Adiponectin/Acrp30 (HEK 293) | Recombinant Proteins |
| Acrp-30; GBP-28; Apm-1 | ||
| Adiponectin is an important adipocytokine involved in the control of fat metabolism and insulin sensitivity. It is made only by fat cells and secreted into plasma. Protein structure: Acrp30 (Lys101-ASN244), Accession # ：Q15848. | ||
| M15024 | Recombinant Human MIP-1α/CCL3 (CHO) | Recombinant Proteins |
| Macrophage Inflammatory Protein-1α; CCL-3; LD78α; LD78 alpha | ||
| Mip-1 Alpha, also known as CCL3, G0S19-1 and SCYA3, LD78 Alpha, is an inflammatory chemokine. Mip-1 α belongs to the CCL chemokine family and has 68% homology with MIP-1β. The mature form of MIP-1α contains 69 amino acids, which are present in solution as dimers and tend to accumulate reversibly. Protein structure: MIP-1α (ALA27-ALA92), Accession # : P10147. | ||
| M20465 | Diaveridine | Others |
| AI3-23935, CCRIS-3784 | ||
| Diaveridine is coccidiostat with anti-parasitic activity and also a dihydrofolate reductase (DHFR) inhibitor preventing folic acid synthesis in species of Pneumocystis. | ||
| M21148 | (R)-CR8 trihydrochloride | CDK |
| CR8, (R)-Isomer trihydrochloride | ||
| (R)-CR8 trihydrochloride, one of the isomers of CR8, is a potent CDK1/2/5/7/9 inhibitor with anti-proliferative and pro-apoptotic effects on CML cell lines. (R)-CR8 trihydrochloride inhibited CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM ), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). | ||
| M21609 | Recombinant Mouse Adiponectin (E. coli) | Recombinant Proteins |
| Acrp-30; GBP-28; Apm-1 | ||
| Adiponectin is a hormone mainly produced by adipocytes. Adiponectin forms a homotrimer and exists as higher order multimers in vivo. Measured by a cell growth inhibitory assay using M1 cells, the ED50 is < 5.0 µg/ml, corresponding to a specific activity of > 2.0 × 102 units/mg. | ||
| M25037 | Cevostamab | Others |
| BFCR 4350A; RG 6160; RO 7187797 | ||
| Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. | ||
| M25298 | Foravirumab | Others |
| CR4098 | ||
| Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III. | ||
| M27766 | (S)-CR8 | CDK |
| (S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM). | ||
| M28125 | BI 639667 | CCR |
| CCR1 antagonist 8 | ||
| BI 639667 (compound 19n), a third azaindazole series compound, is a CCR1 antagonist, with an IC50 of 1.8 nM in Ca2+ flux assay. | ||
| M28439 | CRT0066854 | PKC |
| CRT0066854 is a potent and selective atypical PKC isoenzymes inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively. | ||
| M28714 | CRANAD-28 | Fluorescent Dye |
| CRANAD-28 is a robust fluorescent compound for visualization of amyloid beta plaques. | ||
| M29328 | Paltusotine | Somatostatin Receptor |
| CRN00808 | ||
| Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy. | ||
| M29437 | CRT0066854 hydrochloride | PKC |
| CRT0066854 hydrochloride is a potent and selective atypical PKCs inhibitor. CRT0066854 is against full-length (FL) PKCι, PKCζ, and ROCK-II kinases with IC50 values of 132 nM, 639 nM, and 620 nM, respectively. | ||
| M40749 | CCR8 Antagonist 1 | CCR |
| CCR8 Antagonist 1 is a potent human CCR8 antagonist with a Ki value of 1.6 nM. | ||
| M41671 | Ep300/CREBBP-IN-8 | Histone Acetyltransferase |
| Ep300/CREBBP-IN-8 is a potent and orally active Ep300 and CREBBP inhibitor with IC50s of 0.014 and 0.018 μM, respectively. | ||
| M43420 | OICR-8268 | Ligand for E3 Ligase |
| OICR-8268 is a reversible DCAF1 ligand that binds to the DCAF1 WDR domain with a Kd of 38 nM. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
